The National Genomics Board brings together senior decision makers across the sector, including key civil servants, delivery partners, patient advocates and representatives from research organisations and industry.
The purpose of the Board is to oversee the implementation of the Chief Medical Officer’s 2016 annual report, Generation Genome and the genomic elements of the Life Sciences Industrial Sector Deal.
Its goal is to make sure that the UK remains the world’s leading centre for genomic medicine and research, and to use this position to deliver quantifiable benefits for NHS patients and the life sciences sector.
Terms of Reference
The National Genomics Board will:
- advise the UK government and be a mechanism for collaborative work to harness the benefits of genomics for health
- agree a set of stretching ambitions for healthcare, life sciences and the development of a thriving genomics industry
consider how these working partnerships can contribute to the delivery of these ambitions by:
- establishing and supporting the new NHS Genomic Medicine Service
- creating and implementing a world leading research platform
- ensuring that the UK has the capability and capacity to take full advantage of the research platform
It will make proposals on:
- patient and public involvement
- research activities, skills and training
- genomics and life science industry
- regulatory requirements, policy and guidance
The National Genomics Board will report to the new Life Sciences Council on the relevant aspects of the Life Sciences sector deal. The Life Sciences Council is chaired by the Secretaries of State for Health and Social Care and for Business Energy Industrial Strategy.
The National Genomics Board will report to the Life Sciences Council via the Life Sciences Industrial Strategy Implementation Board.
- Lord O’Shaughnessy, Parliamentary Under Secretary of State for Health (Lords) - chair
- Professor Sir John Bell, vice chair, Regius Professor of Medicine, University of Oxford
- Professor Dame Sally Davies, Chief Medical Officer for England
- Dr Patrick Vallance, Chief Scientific Adviser to UK Government
- David Williams, Director General, Finance and Group Operations, DHSC
- Katie Farrington, Director of Digital and Data, DHSC
- Dr Louise Wood, Director of Science, Research and Evidence, DHSC
- Kristen Mcleod, Director of the Office for Life Sciences, BEIS
- Sir John Chisholm, Executive Chair, Genomics England
- Professor Sir Malcolm Grant, Chair, NHS England
- Professor Sue Hill, NHS Chief Scientific Officer for England, NHS
- Professor Sir Mark Walport, Chief Executive, UK Research and Innovation
- Dr Jeremy Farrar, Director, Wellcome Trust
- Professor Charles Swanton, Chief Clinician, Cancer Research UK
- Professor Fiona Watt, Executive Chair, Medical Research Council
- Professor Sir Alex Markham, Chair, OSCHR subgroup on Health Informatics
- Jayne Spink, Chief Executive, Genetic Alliance
- Deborah Alsina, Chief Executive, Bowel Cancer UK
- Dr Menelas Pangalos, EVP, Innovative Medicines and Early Development, AstraZeneca
- Dr Eliot Forster, Independent industry representative
- Alistair Henderson, Chief Executive, Academy of Medical Royal Colleges
- Dr Tony Wood, Senior Vice President, Platform Technology & Sciences, GSK